Fluconazole in hypercalciuric patients with increased 1,25(OH)2D levels: the prospective, randomized, placebo-controlled, double-blind FLUCOLITH trial

Fluconazole in hypercalciuric patients with increased 1,25(OH)2D levels: the prospective, randomized, placebo-controlled, double-blind FLUCOLITH trial

Abstract Background Hypercalciuria is one of the most frequent metabolic disorders associated with nephrolithiasis and/or nephrocalcinosis possibly leading to chronic kidney disease (CKD) and bone complications in adults. Orphan diseases with different underlying primary pathophysiology share inappr...

Full description

Bibliographic Details
Main Authors: Aurélia Bertholet-Thomas, Aurélie Portefaix, Sacha Flammier, Carole Dhelens, Fabien Subtil, Laurence Dubourg, Valérie Laudy, Myrtille Le Bouar, Inesse Boussaha, Marietou Ndiaye, Arnaud Molin, Sandrine Lemoine, Justine Bacchetta
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Trials
Subjects:
SLC34A1
SLC34A3
CYP24A1
Hypercalciuria
Fluconazole
1,25(OH)2D
Online Access:https://doi.org/10.1186/s13063-022-06302-z

Internet

https://doi.org/10.1186/s13063-022-06302-z

Similar Items